Table 3 Top 10 most common DMTs during each of the first four lines of therapy
Treatment line | Medication | Patient count | Rank in treatment line | % of patients in treatment line |
|---|---|---|---|---|
1 (n = 1994) | Glatiramer | 693 | 1 | 34.8% |
Dimethyl fumarate | 539 | 2 | 27.0% | |
Interferon beta-1a | 152 | 3 | 7.6% | |
Fingolimod | 151 | 4 | 7.6% | |
Teriflunomide | 142 | 5 | 7.1% | |
Ocrelizumab | 120 | 6 | 6.0% | |
Natalizumab | 85 | 7 | 4.3% | |
Interferon beta-1b | 30 | 8 | 1.5% | |
Peginterferon beta-1a | 30 | 8 | 1.5% | |
Rituximab | 28 | 10 | 1.4% | |
2 (n = 563) | Dimethyl fumarate | 117 | 1 | 20.8% |
Teriflunomide | 88 | 2 | 15.6% | |
Ocrelizumab | 83 | 3 | 14.7% | |
Fingolimod | 82 | 4 | 14.6% | |
Natalizumab | 58 | 5 | 10.3% | |
Glatiramer | 55 | 6 | 9.8% | |
Interferon beta-1a | 31 | 7 | 5.5% | |
Interferon beta-1b | 10 | 8 | 1.8% | |
Peginterferon beta-1a | 8 | 9 | 1.4% | |
Glatiramer & Dimethyl fumarate | 7 | 10 | 1.2% | |
3 (n = 115) | Ocrelizumab | 23 | 1 | 20.0% |
Dimethyl fumarate | 21 | 2 | 18.3% | |
Natalizumab | 16 | 3 | 13.9% | |
Teriflunomide | 16 | 4 | 13.9% | |
Fingolimod | 11 | 5 | 9.6% | |
Glatiramer | 10 | 6 | 8.7% | |
Interferon beta-1a | 8 | 7 | 7.0% | |
Alemtuzumab | 4 | 8 | 3.5% | |
Peginterferon beta-1a | 2 | 9 | 1.7% | |
Rituximab | 2 | 9 | 1.7% | |
4 (n = 18) | Ocrelizumab | 7 | 1 | 38.9% |
Alemtuzumab | 3 | 2 | 16.7% | |
Natalizumab | 3 | 3 | 16.7% | |
Glatiramer | 2 | 4 | 11.1% | |
Dimethyl fumarate | 1 | 5 | 5.6% | |
Dimethyl fumarate & Interferon beta-1b | 1 | 5 | 5.6% | |
Teriflunomide | 1 | 5 | 5.6% |